The Flow Cytometry Facility (FCF) is a Shared Resource that provides Cancer Center investigators access to high quality, cost effective flow cytometry services and technology. By providing these services and the scientific expertise necessary to effectively use this technology, the facility serves to enhance the scope and quality of cancer research performed at the University. With state of the art instrumentation, the facility offers high speed 4 way cell sorting and cloning, complex multicolor analytical services, multiplexing assays for soluble analytes, and imaging flow cytometry. This instrumentation is compatible with a wide variety of flow cytometric applications such as subpopulation identification/quantification, molecular detection (using labeled antibodies or other ligands or fluorescent protein reporter molecules), measurement of DNA and RNA content for cell cycle analysis, apoptosis, transcriptional activity, intracellular ion concentration (e.g. Ca++), cell viability, membrane potential, microarrays, and bead based immunoassays. In addition to the instrumentation, the highly experienced staff of the FCF provides consultation in experimental design, sample preparation and data analysis. Researchers have the option, once trained, of performing their own analysis or utilizing the expertise of the facility's staff to run their samples for them. Specialized training classes are offered for those researchers who wish to better understand the principles and techniques employed in this technology and prefer to directly acquire and/or analyze their own samples. The services and expertise offered by the FCF play a key role in the study of many types of cancer, especially hematological malignancies, as well as immune responses to cancers.
Flow cytometry is a mainstay of research on the immune system, and has now broadened its utility to all aspects of cancer research where analysis of single cells is important. As we learn more about the heterogeneity of tumors, this becomes increasingly critical for modern cancer research.
|Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655|
|Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442|
|Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9|
|Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425|
|Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813|
|Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815|
|Kulling, Paige M; Olson, Kristine C; Hamele, Cait E et al. (2018) Dysregulation of the IFN-?-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS One 13:e0193429|
|Grant, Margaret J; Loftus, Matthew S; Stoja, Aiola P et al. (2018) Superresolution microscopy reveals structural mechanisms driving the nanoarchitecture of a viral chromatin tether. Proc Natl Acad Sci U S A 115:4992-4997|
|Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984|
|Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59|
Showing the most recent 10 out of 539 publications